Literature DB >> 30998116

No differences in effectiveness and safety between pipeline embolization device and stent-assisted coiling for the treatment of communicating segment internal carotid artery aneurysms.

Alejandro Enriquez-Marulanda1, Mohamed M Salem1, Luis C Ascanio1, Georgios A Maragkos1, Raghav Gupta1, Justin M Moore1, Ajith J Thomas1, Christopher S Ogilvy1, Abdulrahman Y Alturki1,2.   

Abstract

BACKGROUND: Aneurysms arising from the communicating segment (C7) of the internal carotid artery (ICA) are one of the most frequent locations of intracranial aneurysms. Stent-assisted coiling (SAC) and flow diversion therapies are both endovascular strategies used for the treatment of ICA aneurysms occurring at the C7 segment.
OBJECTIVE: The aim of this study is to compare both methods' angiographic and functional outcomes, and procedural complications. To our knowledge, this is the first study to compare both modalities for aneurysms at this location.
METHODS: A retrospective review was performed of our prospectively collected database from 2008 until 2017 for patients treated with SAC and from 2013 until 2017 for patients treated with pipeline embolization devices (PEDs).
RESULTS: We identified 35 patients for this cohort with 38 aneurysms; 17 treated with SAC and 21 with PED. Mean age was 59 years, and 30 patients were female (86%). Complete occlusion at last follow-up occurred in 70.6% of patients in the SAC group and in 81% in the PED group (p = 0.45). Posterior communicating artery patency at last follow-up did not differ significantly between the two groups (94.1% vs 85.7%; p = 0.40). Good functional outcome at last follow-up (mRS 0-2) was achieved in 100% and 88.2% of patients, respectively. Additionally, there was no significant difference between the two groups for retreatment rates, procedural hemorrhagic, or thromboembolic complications.
CONCLUSION: SAC and PED are two equally efficacious modalities for endovascular treatment of ICA aneurysms arising at the communicating segment of the ICA.

Entities:  

Keywords:  Intracranial aneurysm; comparison; flow diversion; internal carotid artery; pipeline embolization device; posterior communicating artery aneurysm; stent-assisted coiling

Mesh:

Year:  2019        PMID: 30998116      PMCID: PMC6728696          DOI: 10.1177/1971400919845368

Source DB:  PubMed          Journal:  Neuroradiol J        ISSN: 1971-4009


  5 in total

1.  The Safety and Efficacy of Flow Diversion versus Conventional Endovascular Treatment for Intracranial Aneurysms: A Meta-analysis of Real-world Cohort Studies from the Past 10 Years.

Authors:  S Li; C Zeng; W Tao; Z Huang; L Yan; X Tian; F Chen
Journal:  AJNR Am J Neuroradiol       Date:  2022-06-16       Impact factor: 4.966

2.  Complex cerebral aneurysms: intra-luminal reconstruction using Pipeline flow-diverting stent and the obliteration mechanism.

Authors:  Xianli Lv; Chuhan Jiang; Zhongxue Wu; Weijian Jiang; Guihuai Wang
Journal:  Neuroradiol J       Date:  2019-12-11

3.  Flared non-flow diverting ends of the FRED flow diverter for cerebral aneurysms facilitate device anchoring at the arterial bifurcation.

Authors:  Jan-Karl Burkhardt; Laura Stone McGuire; Christoph J Griessenauer
Journal:  Neuroradiol J       Date:  2021-05-04

4.  Efficacy of pipeline embolization device vs. traditional coils in embolization of intracranial aneurysms: A systematic review and meta-analysis.

Authors:  Wei Li; Zaixing Xiao; Kaixuan Zhao; Shijie Yang; Yichuan Zhang; Bin Li; Yu Zhou; Yong Ma; Erqing Chai
Journal:  Front Neurol       Date:  2022-09-29       Impact factor: 4.086

5.  Endoluminal flow diverters in the treatment of sidewall and bifurcation aneurysm: A systematic review and meta-analysis of complications and angiographic outcomes.

Authors:  Mehdi Abbasi; Luis E Savasatano; Waleed Brinjikji; Kevin M Kallmes; Nick Mikoff; Natalie Reierson; Mohamed Abdelmegeed; John Pederson; Beth Warren; Jillienne C Touchette; Sarah Khan; Shelby Kamrowski; Averi Barrett; David F Kallmes; Ramanathan Kadirvel
Journal:  Interv Neuroradiol       Date:  2021-06-22       Impact factor: 1.764

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.